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Key Points
• Survival after transplan-
tation for NMDs is ex-
cellent beyond the first
2 years post-HCT.
•Cumulative incidence
of SNs is low; however,
there is an increased
risk in those with FA or
marrow failure.
We examined the risk of subsequent neoplasms (SNs) and late mortality in children and
adolescents undergoing allogeneic hematopoietic cell transplantation (HCT) for
nonmalignant diseases (NMDs).We included6028patients (medianage, 6 years; interquartile
range, 1-11; range,,1 to 20) from the Center for International Blood andMarrow Transplant
Research (1995-2012) registry. Standardized mortality ratios (SMRs) in 2-year survivors and
standardized incidence ratios (SIRs) were calculated to compare mortality and SN rates with
expected rates in the general population. Median follow-up of survivors was 7.8 years.
Diagnoses included severe aplastic anemia (SAA; 24%), Fanconi anemia (FA; 10%), other
marrow failure (6%), hemoglobinopathy (15%), immunodeficiency (23%), and metabolic/
leukodystrophy syndrome (22%). Ten-year survival was 93% (95% confidence interval [95%
CI], 92% to 94%; SMR, 4.2; 95% CI, 3.7-4.8). Seventy-one patients developed SNs (1.2%).
Incidence was highest in FA (5.5%), SAA (1.1%), and othermarrow failure syndromes (1.7%);
for other NMDs, incidence was ,1%. Hematologic (27%), oropharyngeal (25%), and skin
cancers (13%) were most common. Leukemia risk was highest in the first 5 years
posttransplantation; oropharyngeal, skin, liver, and thyroid tumors primarily occurred after
5 years. Despite a low number of SNs, patients had an 11-fold increased SN risk (SIR, 11; 95%
CI, 8.9-13.9) compared with the general population. We report excellent long-term survival
and low SN incidence in an international cohort of children undergoing HCT for NMDs. The
risk of SN development was highest in patients with FA and marrow failure syndromes,
highlighting the need for long-term posttransplantation surveillance in this population.
Introduction
Allogeneic hematopoietic cell transplantation is a curative treatment
option for pediatric and adolescent patients with nonmalignant
diseases (NMDs). Despite continued advances in the field of HCT
and an increasing number of long-term survivors, treatment-related
mortality and late effects remain a challenge. A significant cause of
morbidity after HCT is the development of subsequent neoplasms
(SNs).1 Among children receiving transplants for primary malignan-
cies, exposure to cytotoxic therapy or radiation during initial cancer
treatment followed by myeloablative conditioning before HCT
increases the likelihood of SN posttransplantation. (HCT). Presumably,
children and adolescents receiving transplants for NMDs are at lower
risk for SNs than might be expected in children undergoing HCT for
malignant diseases. However, although a majority of these patients are
not exposed to prior chemotherapy or radiation, graft-versus-host
disease (GVHD), immunosuppressive therapy, and genetic predispo-
sition may also increase the risk of SN posttransplantation.
Numerous studies have described SN incidence in children and
adolescents undergoing HCT for the treatment of primary malignan-
cies2; however, few have examined SN risk in those undergoing
transplantation for NMDs.3 Given the increasing use of HCT for
children with NMDs, data regarding these long-term outcomes are of
high importance. A recent report from the National Institutes of Health
Hematopoietic Cell Transplantation Late Effects Initiative highlighted
gaps in the current literature regarding SNs after HCT.1 Authors cited
a need for longitudinal studies and for comparison of SN risk after HCT
with the risk of new malignancies in the general population.4
The objectives of this study were to examine the incidence of
posttransplantation SNs and report the risk of death after 2 years in
an international cohort of pediatric and adolescent patients with
bone marrow failure disorders, hemoglobinopathies, immunodefi-
ciency syndromes, inborn errors of metabolism, and leukodystro-
phies. We specifically examined whether patients had an increased
risk of developing a new malignancy at any time point and an
increased risk of late mortality compared with the general
population of age- and sex-matched controls. Here we report
contemporary data on a diverse patient population to both inform
decision making and contribute to consensus guidelines about
posttransplantation follow-up surveillance in children and adoles-
cents receiving transplants for NMDs.5
Patients and methods
Data source
The Center for International Blood and Marrow Transplant Re-
search (CIBMTR), a research collaboration between the Medical
College of Wisconsin and the National Marrow Donor Program,
collects data from .450 transplantation centers worldwide.
Participating centers contribute data about individual patients,
their exposures, and their outcomes. Transplant essential data
are collected on all patients and include information on de-
mographics, primary disease, transplantation characteristics, and
posttransplantation outcomes (including SNs, relapse, survival, and
cause of death). Observational studies conducted by the CIBMTR
are performed in compliance with all applicable federal regulations
pertaining to the protection of human research participants.
Study cohort
The study cohorts included in analyses of survival and SNs are
presented in Figure 1. Children and adolescents undergoing first
HCT for treatment of Fanconi anemia (FA), severe aplastic anemia
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(SAA), other marrow failure disorders, sickle cell disease (SCD),
thalassemia, primary immunodeficiency syndromes (PIDs), histio-
cytic disorders, or inborn errors of metabolism or leukodystrophy
with data reported to the CIBMTR were eligible for inclusion. A total
of 6028 patients age ,21 years who underwent transplantation
between 1995 and 2012 met inclusion criteria (Figure 1).
For analysis of late mortality and long-term survival, patients who
died (n5 1524; 25%) or who were lost to follow-up before 2 years
(n 5 251; 5%) were excluded. For analysis of SNs, incidence of
SNs for each NMD group was determined from the time of
transplantation to the time of event. Patients without information on
SNs and those who had an SN diagnosis date that preceded the
date of HCT were excluded. An additional 48 patients were
excluded from calculation of SN standardized incidence ratios
(SIRs) because general population cancer rates were not available
for their countries of origin; these included patients from South
Africa (n5 33), Venezuela (n5 7), Mexico (n5 7), and Croatia (n5
1). Posttransplantation lymphoproliferative disorder (PTLD) was not
included as an SN. The final population for SIR analysis of SNs
included 5933 patients (Figure 1).
Statistical analyses
The primary objectives of this study were to report the incidence of
late mortality (defined as death in patients surviving at least 2 years
posttransplantation) and the risk of SNs in children and adolescents
receiving transplants for NMDs and assess whether those risks
were increased relative to the general population of age- and sex-
matched controls. Overall survival (OS) was calculated from 2 years
after the date of transplantation until the date of death (or last
contact for those who remained alive). Survival probabilities were
estimated by the Kaplan-Meier method. Standardized mortality
ratios (SMRs) with 95% confidence intervals (CIs) were used to
compare observed mortality in the study population with expected
mortality in the general population of age- and sex-matched controls
in each country. Expected mortality was calculated from standard-
ized actuarial tables in National Vital Statistics Reports6 and the
Human Mortality Database.
In total, 86 pathology reports were requested from CIBMTR sites.
Of these, 15 were removed because of misclassification of SNs.
After review, 71 SN events were eligible for inclusion, 55 of which
had enough accompanying information to be assigned an Interna-
tional Statistical Classification of Diseases and Related Health
Problems, 10th edition (ICD-10), code. For analysis of SN incidence
relative to the general population, the number of person-years at risk
was calculated from the date of HCT until the date of last contact,
SN diagnosis, or death. Incidence rates for all invasive cancers in
the general population were obtained from selected registries
worldwide.7-9 The risk of new malignancy in the study cohort was
compared with that in the general population using in the method of
Breslow et al,12 as described in previous CIBMTR studies.10-12 To
Center for International Blood and Marrow Transplant Research (CIBMTR)
Registry
Patients 21 years undergoing first allogeneic hematopoietic cell
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compute expected numbers of cancers in the population, age, sex,
calendar year, and region-specific incidence rates for all invasive
solid cancers combined and for cancers of specific anatomic sites
individually were applied to the appropriate person-years at risk.
All reported cases of SNs (with or without pathologic confirmation)
that occurred after the date of HCT were treated as events (n 5
71). Observed/expected ratios, also called SIRs, were calculated
for each NMD group, and the exact Poisson distribution was used
to calculate 95% CIs.10 For tumor site–specific SIR calculations,
only cases to which we were able to assign an ICD-10 code were
included (n 5 55). A significance level a of 5% was used
throughout.
Finally, multivariable Cox proportional hazards regression analyses
were used to identify risk factors for SN development across the full
patient cohort and in patients with FA or SAA and are presented as
hazard ratios (HRs) with 95% CIs. Variables included in multivari-
able analyses were based on past research and known risk factors
for SNs posttransplantation from prior studies. Models were
adjusted for age, donor and stem cell source, myeloablative
conditioning (vs reduced intensity or nonmyeloablative), receipt of
total-body irradiation (TBI), and diagnosis of chronic GVHD. All
analyses were performed with SAS software (version 9.4; SAS
Institute, Cary, NC).
Results
Patient, disease, and transplantation characteristics
A summary of patient, disease, and transplantation characteristics is
presented in Table 1. Median age at HCT was 6 years (interquartile
range [IQR], 1-11; range, ,1 to 20), and median follow-up was
7.8 years (IQR, 5.0-11.1; range, ,1 to 20); 22% of the cohort had
at least 10 years of follow-up. Forty percent of the cohort had
congenital or acquired bone marrow failure disorders, including FA
(10%) and SAA (24%). Patients with hemoglobinopathies com-
prised 15% of the cohort (SCD, 5%; thalassemia, 10%). Twenty-
three percent of patients had either SCID or non-SCID PIDs, and
22% had inborn errors of metabolism, leukodystrophy, or
Table 1. Patient and transplantation characteristics (N 5 6028)
Characteristic n (%)
Follow-up of survivors, y
Median 7.8
IQR 5-11.1
Range ,1 to 20
Age at transplantation, y
Median 6
IQR 1-11




Region of transplantation center
United States 3290 (55)
Canada 195 (3)
Europe 816 (13)
India and Asia 307 (5)
Middle East and Africa 697 (12)
Central and South America 463 (8)








Bone marrow failure disorder 2405 (40)
SAA 1456 (24)
FA 598 (10)




Immunodeficiency syndrome 1415 (23)
SCID 583 (10)
Non-SCID PID 807 (13)
Histiocytic disorder 469 (8)
Metabolic disease, leukodystrophy, other 1334 (22)
Metabolic disorder 476 (8)
Leukodystrophy 227 (4)
Osteopetrosis 150 (2)




TBI 1 Cy 6 other 894 (15)
TBI 1 other 117 (2)
Bu 1 Cy 2720 (45)
Table 1. (continued)
Characteristic n (%)
Bu 1 other (not Cy) 309 (5)
Cy 1 other (no Bu) 1239 (21)
Fludarabine 1 other 493 (8)
Other 115 (2)
Graft type
Bone marrow 3922 (65)
Peripheral blood 553 (9)
Cord blood 1553 (26)
Donor
HLA-identical sibling 2298 (38)
Other related 482 (8)
Unrelated 1695 (28)
Cord blood 1553 (26)
Bu, busulfan; Cy, cyclophosphamide; SCID, severe combined immunodeficiency.
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osteopetrosis. A majority of patients received myeloablative
conditioning (63%); however, only 17% of these regimens included
TBI. A total of 71% of patients received antithymocyte globulin
either as pretransplantation conditioning or as part of GVHD
prophylaxis. Most patients received bone marrow as a stem cell
source (65%). HLA-identical sibling (38%) or unrelated donors
(17%) were most common (Table 1).
OS and relative mortality among 2-year survivors
A total of 4214 patients (70%) with at least 2 years of follow-up
were included in analysis of late mortality; 1524 (25%) died before
2 years, and 251 (4%) were excluded because of incomplete data
at 2 years posttransplantation. Of the 25% of patients who died
before 2 years, the primary causes of death were organ failure
(23%) and infection (22%), followed by pulmonary complications
(12%) and GVHD (10%; Table 2). OS probabilities among the
patients still alive after 2 years were 97% (95% CI, 96% to 97%)
and 93% (95% CI, 92% to 94%) at 5 and 10 years, respectively
(Table 3). Long-term survival in this cohort varied based on
underlying NMD. Patients with inborn errors of metabolism or
leukodystrophies had the lowest survival probabilities at each
evaluable time point (Table 3). The most common cause of death in
2-year survivors was organ failure (20%), followed by complications
of primary disease (17%), infection (11%), and GVHD (10%).
Subsequent neoplasms were the cause of death in 6% of cases
(Table 2).
Comparisons of mortality rates in each disease group with rates in
the general population are presented in Table 2. Although long-term
survival was excellent, the study cohort alive at 2 years still had
a fourfold increased incidence of all-cause mortality compared with
age- and sex-matched controls from the general population (SMR,
4.2; 95% CI, 3.7-4.8). Mortality rates for all NMDs were significantly
higher than rates in the general population, with the exception of
patients with thalassemia or autoimmune disease. Increased mortality
rate was most dramatically noted in children with inborn errors of
metabolism or leukodystrophies, whose risks of death were 37- and
25-fold higher than expected, respectively (Table 2).
SNs
Among 5933 patients with median follow-up of 7.6 years (range,
2-20.9), 71 (1.2%) developed SNs. Details of the 71 individual
cases are presented in supplemental Table 1. Incidence of SNs was
highest in children with FA (5.5%), SAA (1.1%), or other marrow
failure disorders (1.7%; Table 4). In patients with hemoglobinop-
athies, PIDs, metabolic disorders, leukodystrophies, or other NMDs,
SN rates were ,1%. No SNs were observed in patients receiving
transplants for thalassemia. The most frequent SNs were hemato-
logic malignancies, including acute myeloid leukemia (AML; n 5 8),
myelodysplastic syndrome (MDS; n 5 7), and acute lymphoblastic
leukemia (n 5 3). Oropharyngeal cancers, including mouth (n5 2),
tongue (n5 5), and hypopharynx (n5 1), comprised 25% of cases.
Skin cancers, including melanoma (n 5 2), were diagnosed in 9
patients (Table 4).
The observed incidence of SNs posttransplantation was signifi-
cantly higher than the expected incidence in the general population
(SIR, 11; 95% CI, 8.9-13.9; Table 5). Excess risk was evident in
those receiving transplants for FA (SIR, 50; 95% CI, 34-71),
SAA (SIR, 8; 95% CI, 4-12), or SCD (SIR, 11; 95% CI, 2-33).
Patients with leukodystrophy or histiocytic disorders had 10-
(95% CI, 1-37) and 14-fold (95% CI, 5-33) higher-than-expected
incidence of SNs, respectively. Posttransplantation SN incidence
was not significantly higher than expected in patients undergoing
transplantation for thalassemia, PIDs, osteopetrosis, or metabolic
disorders (Table 5).
Tumor site–specific comparisons of SNs in the study cohort with
the general population were restricted to the 55 cases assigned
ICD-10 codes. Analysis revealed that risk in the study cohort was
elevated for almost all cancer sites (Table 5). Compared with the
general population, the study cohort had significantly increased
rates of AML (SIR, 23; 95% CI, 9.7-44) and MDS (SIR, 730; 95%
CI, 293 to .1000), as well as increased rates of oropharyngeal,
skin, thyroid, liver, and bladder tumors. Of particular note were
the higher-than-expected rates of tongue (SIR, 490; 95% CI,
159 to .1000) and mouth tumors (SIR, 113; 95% CI, 14-408),
which developed exclusively in patients receiving transplants for
FA or marrow failure syndromes. Patients in the study cohort also had
higher-than-expected rates of nonmelanomatous skin cancer (SIR, 68;
95% CI, 27-140). The incidence of bone cancer and central nervous
system tumors was not significantly higher in the study cohort than
would be expected in the general population.
In the full cohort of patients, multivariable models revealed that TBI-
based conditioning was associated with a significantly higher
hazard of SNs. Specifically, patients who received a TBI-based
conditioning regimen had a 2.5-fold higher hazard of developing
a posttransplantation SN compared with those who did not receive
TBI-based conditioning (HR, 2.5; 95% CI, 1.5-4.1; P 5 .0003).
Among patients with FA, nonmyeloablative conditioning was
associated with a 75% reduction in the hazard of SNs (HR, 0.26;
95% CI, 0.1-0.9; P 5 .0271). Development of chronic GVHD in
patients with FA was associated with a 4.8-fold increased hazard of
SN development (HR, 4.8; 95% CI, 2.3-10.4; P ,.0001).
Median time from HCT to SN development was 7.5 years (IQR, 3.5-
10.4; range, 0.04-18.5; Figure 2). Median latency between trans-
plantation and SN was shortest for AML (median, 1.8 years; IQR,
1.0-3.7). Latency was longer for cancers of the oropharynx (median,
10.2 years; IQR, 8.2-14.5), as well as for skin (median, 7.2 years;
IQR, 2.9-7.9) and other solid tumors (median, 8.6 years; IQR, 6.1-
10.6; Figure 2). Information on 71 individual SN cases with details
Table 2. Cause of death <2 vs ‡2 years posttransplantation (N5 6028)
Primary cause of death <2 y, n (%) ‡2 y, n (%) Total, n (%)
Patients, n 1524 251 1775
Primary disease 104 (7) 43 (17) 147 (8)
Graft failure 87 (6) 9 (4) 96 (5)
GVHD 151 (10) 26 (10) 177 (10)
Infection 332 (22) 28 (11) 360 (20)
Pulmonary/ARDS 182 (12) 11 (4) 193 (11)
Organ failure 348 (23) 50 (20) 398 (22)
Secondary malignancy 19 (1) 14 (6) 33 (2)
Other cause 147 (10) 33 (13) 180 (10)
Unknown 2 (0) 0 (0) 2 (0)
Missing 152 (10) 37 (15) 189 (11)
ARDS, acute respiratory distress syndrome.
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about primary NMD, pretransplantation conditioning, TBI, and
GVHD is presented in supplemental Table 1.
Discussion
To our knowledge, this is the largest study examining SN incidence
and late mortality in an international cohort of children and
adolescents receiving transplants for NMDs. Findings indicate that
a majority of patients who undergo HCT for treatment of NMDs and
are still alive after 2 years have excellent long-term survival. These
findings, while encouraging, underscore the fact that despite low
cumulative incidence of late mortality, the risk of early death remains
a significant challenge in the pediatric transplantation population.
Furthermore, the risk of death resulting from GVHD, infection, or
organ failure persists over time, particularly in those undergoing
transplantation for inborn errors of metabolism or leukodystrophies.
Table 3. Survival probabilities at 5 and 10 years in patients alive ‡2 years post-HCT, with corresponding SMRs, by NMD
Primary disease n (%) 5 y (95% CI) 10 y (95% CI) SMR (95% CI) P
Patients alive $2 y post-HCT n 5 4214 97 (96-97) 93 (92-94) 4.2 (3.7-4.8) ,.0001
Bone marrow failure disorder
SAA 192 (5) 98 (97-99) 95 (93-97) 1.8 (1.3-2.4) .0009
FA 393 (9) 96 (94-98) 92 (88-95) 4.8 (3.4-6.6) ,.0001
Other marrow failure 242 (6) 95 (91-97) 93 (88-96) 6.4 (3.8-10) ,.0001
Hemoglobinopathy
Thalassemia 401 (10) 98 (97-99) 98 (97-99) 0.7 (0.3-1.4) .3942
SCD 247 (6) 97 (94-99) 96 (93-98) 8.3 (3.9-15) ,.0001
Immunodeficiency syndrome
SCID 403 (10) 97 (95-98) 93 (90-96) 4.8 (3.0-7.3) ,.0001
Non-SCID PID 607 (14) 97 (96-99) 95 (93-97) 5.0 (3.3-7.4) ,.0001
Histiocytic disorder 273 (6) 98 (96-99) 94 (89-97) 9.3 (4.8-16) ,.0001
Inborn error of metabolism, leukodystrophy, other
Metabolic disorder 314 (7) 93 (89-95) 86 (81-90) 25 (18-5) ,.0001
Leukodystrophy 143 (3) 89 (83-94) 75 (64-84) 37 (37-53) ,.0001
Osteopetrosis 77 (2) 93 (86-98) 85 (74-93) 11.5 (5.5-21) ,.0001
Autoimmune disease 12 (,1) 100 83 (46-100) 12.9 (0.3-72) .1498
Table 4. Incidence of SNs by primary NMD with SIRs (N 5 5933)
Primary NMD n of survivors (median follow-up, y; range) Reported SNs, n (%) SIR (95% CI) P
Total 5933 (7.6; 0-20.9) 71 (1.2) 11 (9-14) ,.001
Bone marrow failure disorder
SAA 1429 (7.6; 0-20.8) 16 (1.1) 8 (4-12) ,.001
FA 574 (9.1; 0.2-20.4) 31 (5.4) 50 (34-71) ,.001
Other marrow failure 343 (7.7; 0.6-20.3) 6 (1.7) 15 (5-32) ,.001
Hemoglobinopathy
SCD 294 (6.1; 0.1-20.1) 3 (1) 11 (2-33) .005
Thalassemia 572 (5.3; 0.2-20.0) 0 (0) — —
Immunodeficiency syndrome
SCID 575 (7.3; 0.2-20.9) 2 (0.3) 4 (0.5-14) .196
Non-SCID PID 793 (8.0; 0.2-20.5) 3 (0.4) 4 (0.7-10) .107
Histiocytic disorder 466 (7.1; 0.5-20.2) 5 (1) 14 (5-33) ,.001
Metabolic disease, leukodystrophy, other
Leukodystrophy 227 (6.1; 0.2-20.2) 2 (0.9) 10 (1-37) .034
Osteopetrosis 150 (6.9; 0.2-20.2) 1 (0.7) 10 (0.3-56) .191
Metabolic disorder 474 (8.3; 0.2-20.4) 2 (0.4) 4 (0.5-15) .172
Autoimmune 24 (4.7; 0.3-15.8) 0 (0) — —
Other 12 (8.7; 5.5-14.0) 0 (0) — —
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Despite our cohort having higher-than-expected mortality when
compared with the general population, a majority of patients who
remained alive 2 years posttransplantation had high survival rates at
both 5 and 10 years. With the exception of patients undergoing
transplantation for FA, the study cohort had a reassuringly low
cumulative incidence of posttransplantation SNs.
The cumulative incidence of mortality in our long-term survivors is
similar to other recent reports of patients undergoing allogeneic
HCT for NMDs. In a recent study examining posttransplantation
mortality in patients still alive at 2 years, the 20-year OS rate by
primary diagnosis was 92% for immune disorders, 91% for SAA,
82.3% for sickle cell anemia or thalassemia, and 68.5% for FA.
When compared with the general population, the relative mortality
in patients undergoing transplantation between 2000 and 2010
was actually higher than in earlier time periods. The authors
suggested this could be related to the relatively lower rate of
childhood death resulting from other causes. Overall, they noted
that the cumulative incidence of late mortality decreased signif-
icantly over time from 1990 to 2010.13 In 2007, Bhatia et al14
reported 5- and 10-year survival outcomes in patients with SAA of
96% and 94%, respectively.
For children in our cohort who received transplants for FA, SAA, or
marrow failure, 10-year survival probabilities were .90%. In our
analysis, which was restricted to patients still alive at 2 years,
survival probabilities at 5 and 10 years for patients with SAA were
98% and 95%, respectively. These rates are substantially higher
than earlier reports of outcomes in SAA,15 which may be related to
the younger age of our cohort or continued improvements in the
transplantation procedure, as has been suggested in other recent
reports. It should be noted that the present analysis, in contrast to
prior studies, did not include 1-year transplantation-related mortal-
ity, which may also have contributed to the relatively improved
outcomes. Similar to recent studies reporting survival outcomes
near 100% in children receiving matched sibling donor transplants
for SCD, we observed excellent long-term survival in this group, with
5- and 10-year survival probabilities of 97% and 96%, respec-
tively.16 We observed no excess risk of death in patients receiving
transplants for thalassemia. In 2012, Bernardo et al17 reported
5-year survival of 93% in younger patients undergoing trans-
plantation for thalassemia, which is closer to the probabilities
observed in our cohort.
We observed favorable long-term survival in patients with PIDs,
which has been reported by others, although inconsistently.3,18 Pai
et al19 reported that in patients who receive transplants before the
onset of infection, excellent survival is expected in infants with
SCID. Survival in our cohort was similar to that of the younger
patients.20 Again, differences in mortality risk observed between our
study and earlier studies may in part be attributed to differences in
cohort selection criteria (1- vs 2-year survivors). Few studies have
reported long-term outcomes in patients undergoing transplanta-
tion for histiocytic disorders. We observed that survival for these
patients was excellent at both 5 and 10 years (98% and 94%,
respectively).
Ten-year survival probabilities in patients with inborn errors of
metabolism or leukodystrophies ranged from 75% to 86%. In an
analysis of OS in children undergoing cord blood transplantation for
leukodystrophies, Van den Broek et al21 reported similar survival
probabilities to those observed in our cohort despite not restricting
their study to 2-year survivors. Survival probabilities were similar to
what we observed in our cohort, suggesting that the risk of
posttransplantation mortality, which is often highest in the early
posttransplantation period, may persist over time in this patient
population.
Overall, the study cohort had a low incidence of posttransplantation
SNs (1.2%). With median follow-up of nearly 8 years, SN incidence
was 5.5% in patients with FA and 1.1% in patients with SAA.22
These rates are slightly lower than those of prior reports in this
patient population with similar length of follow-up.23 In one of the
earliest studies examining posttransplantation SN rates, Socié
et al24 reported an 8-year SN incidence up to 22% in children
receiving transplants for SAA. More recent studies with longer
follow-up have reported higher rates of SNs, which may reflect the
long latency between transplantation and SN development. In
2014, the European Group for Blood and Marrow Transplantation




cases, n (%) or n SIR (95% CI)* P
Head and neck 18 (25)
Tongue 5 490 (159 to .1000) ,.001
Mouth 2 113 (14-408) ,.001
Oropharynx 2 .1000 (309 to .1000) ,.0001
Hypopharynx 1 .1000 (32 to .1000) .002
Nose, sinuses 1 47 (1.2-264) .042
Oropharynx, unspecified 7 — —
Hematologic 19 (27)
Lymphoid leukemia 3 3 (0.65-9) .143
Myeloid leukemia 8 23 (9.7-44) ,.001
MDS 7 730 (293 to .1000) ,.001
MDS, unspecified 1 — —
Skin 9 (13)
Melanoma of the skin 2 7 (0.8-25) .071
Nonmelanoma skin 7 68 (27-140) ,.001
Bone and soft tissue 7 (10)
Connective, soft tissue 2 6 (0.8-23) .083
Bone 2 6 (0.7-21) .096
Sarcoma, unspecified 3 — —
Thyroid 5 (7) 16 (5.2-37) ,.001
GI/GU 7 (10)
Liver 2 28 (3-100) .005
Cervix uteri 1 13 (0.3-74) .145
Testis 1 3 (0.1-15) .607
Bladder 1 42 (1.0-234) .047
GI/GU, unspecified 2 — —
Brain, CNS 2 (3) 2 (0.3-8) .473
Breast 1 (1) 10 (0.3-58) .184
Other, unspecified 3 (4) — —
CNS, central nervous system; GI, gastrointestinal; GU, genitourinary.
*Based on number of SN cases with assigned ICD-10 codes (n 5 55).
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reported that cumulative incidences of SNs after transplantation in
patients with FA were 21% at 15 years and 34% at 20 years post-
HCT.25
Our observation that patients with FA had an increased SN risk
compared with the general population is consistent with other
studies of FA patients. Even in the absence of HCT, the underlying
genetic instability associated with FA renders these patients at
increased risk for head and neck tumors, as well as for hematologic
and solid malignancies.26 In patients with FA who undergo HCT,
exposure to TBI or alkylating agents, immunosuppression, and
GVHD development have been associated with SN development.
We observed that chronic GVHD was a significant risk factor for
SN development in patients with FA. The use of non–TBI-based
conditioning regimens is increasingly common in recent decades.
Whether this practice shift will reduce the rates of SNs in this
population remains to be seen.
Rates of posttransplantation SNs were low in patients undergoing
transplantation for SCD or thalassemia. Studies in patients with
thalassemia have reported that rates of posttransplantation SNs are
similar to rates in patients who do not undergo HCT.27 In our cohort,
we did not observe any SNs in patients with thalassemia. Recently,
Keegan et al28 reported a higher incidence of leukemia in patients
with SCD compared with the general population. However, in our
cohort, SN risk after transplantation for SCD was not increased
compared with the general population. It is plausible that treatment
of SCD, a disease that is confined exclusively to the hematopoietic
system, may have reduced the likelihood of developing MDS or
leukemia later on.
Patients with PIDs also had low rates of posttransplantation SNs.
Historically, patients with PIDs may be at a higher risk of developing
PTLD in the early post-HCT period. In our study, the incidence of
SNs in patients receiving transplants for primary immunodeficien-
cies was ,1%; however, PTLD was not included as an SN for the
purposes of the present study. Patients with histiocytic disorders
had an SN rate of 1.1%, which was significantly higher than
expected in the general population. Oropharyngeal, mucosal, and
nonmelanomatous skin cancers were the most common non-
hematologic SNs observed in our cohort. All patients with
oropharyngeal cancers had an underlying diagnosis of FA
(supplemental Table 1). Timing of SN development in our cohort
was similar to that in other reports.29 In addition to early leukemia
and skin cancer, we observed a long-term risk for thyroid,
oropharyngeal, and liver tumors, as well as a persistent risk for
MDS. A majority of nonleukemic SNs occurred $5 years post-
HCT.
A strength of this study is the large, international cohort of children
and adolescents, with detailed treatment information and long
duration of follow-up. The analysis builds on earlier work from the
CIBMTR, which examined mortality rates in long-term survivors after
HCT for primary malignancy or SAA before 2004.14,30 The present
analysis extends this work, with 8 more years of data in a cohort with
a broader spectrum of NMDs. Similar to other reports, we found that
TBI is still associated with a higher hazard of SNs, and early
posttransplantation mortality rates remain unacceptably high. We
were unable to evaluate pretransplantation organ dysfunction
related to underlying disease, which could have contributed to
survival outcomes, particularly in patients with metabolic syndromes
or leukodystrophies. For data collected through the CIBMTR, there
is central pathology review for SN cases, and we were unable to
obtain enough data to assign ICD-10 codes for 16 of the reported
cases. These SNs were not included in the analysis of relative
incidence; therefore, the true SIR for some NMD groups and some
site-specific cancer diagnoses may have been underestimated.
Long-term follow-up beyond 10 years was only available in a subset
of our cohort, which also may have led to underestimation of SN
risk, because many malignancies often develop beyond 15 years
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Figure 2. Median time to SN development after
HCT. Median time to SNs for all new diagnoses was
7.5 years (IQR, 3.5-10.4; range, ,1 to 18.5). Median
time to SNs by tumor type was as follows: AML:
1.8 years (IQR, 1.0-3.7; range, ,1 to 7.5); acute
lymphoblastic leukemia (ALL): 2.7 years (IQR, ,1 to
3.6; range, ,1 to 3.6); MDS: 4.2 years (IQR, 3.8-7.7;
range, ,1 to 10.2); skin: 7.2 years (IQR, 2.9-7.9;
range, ,1 to 11.3); oropharyngeal: 10.2 years (IQR,
8.2-14.5; range, 1-18.5); solid tumors: 8.6 years
(IQR, 6.1-10.6; range, ,1 to 17.9); and other SNs,
unspecified: 14.6 years (IQR, ,1 to 18.1; range,
,1 to 18.1).
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determine longer-term survival and later SN development in this
patient cohort.
In summary, we report excellent long-term survival in patients still
alive at 2 years, as well as low incidence of posttransplantation SNs,
in an international cohort of children and adolescents undergoing
transplantation for NMDs. These findings are accompanied by
a recognition that early posttransplantation mortality remains
a significant challenge and that the risk for SN development
persists over time. The patients at highest risk of developing SNs
were those who might have had underlying predispositions
to malignancy, specifically patients with FA or marrow failure
disorders. In the full cohort, TBI-based conditioning regimens were
associated with a significantly higher hazard of SN development; in
patients with FA, the hazard of SNs was significantly higher in those
with chronic GVHD. We observed no excess cancer risk in children
receiving transplants for thalassemia, PIDs, osteopetrosis, and
metabolic disorders. The present findings suggest that in the
absence of individual patient susceptibility, the transplantation
procedure itself may not necessarily increase the likelihood of
developing a malignancy. It is important to note that a majority of
nonleukemic SNs developed at least 5 years posttransplantation,
which highlights the need for long-term surveillance and close
follow-up in children and adolescents undergoing transplantation
for NMDs.31
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